Summary & Overview
HCPCS J9048: Bortezomib (Fresenius Kabi) Injection, 0.1 mg
HCPCS Level II code J9048 denotes a 0.1 mg unit of bortezomib manufactured by Fresenius Kabi and billed as an injectable antineoplastic agent distinct from therapeutically equivalent products billed under J9041. This product-level HCPCS code matters nationally because it facilitates precise billing for specific manufacturer formulations, affects claims routing in outpatient infusion and hospital settings, and can influence coverage distinctions at the payer-product level.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for bortezomib as an injectable chemotherapy agent, typical sites of service where J9048 is billed, and the implications of manufacturer-specific HCPCS coding on payer adjudication. The publication outlines expected benchmarks and policy-relevant topics such as differences among product-specific HCPCS codes, impacts on prior authorization and reimbursement workflows, and considerations for billing precision when multiple manufacturer formulations exist.
Where specific payer policy details or claim-level benchmarks are not provided in the input, the document notes that those data are not available and focuses on national coding and clinical-billing context to inform coding accuracy and administrative planning.
Billing Code Overview
HCPCS Level II code J9048 represents an injection of bortezomib (Fresenius Kabi), not therapeutically equivalent to J9041, in a 0.1 mg unit. This code describes the specific biologic/chemotherapy product formulation and unit-based dosing for billing purposes.
Service Type: Injectable chemotherapy/antineoplastic agent
Typical Site of Service: Outpatient infusion center or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J9048 is an adult oncology outpatient with a diagnosis such as multiple myeloma or mantle cell lymphoma who requires systemic proteasome inhibitor therapy. The medication J9048 denotes bortezomib supplied by Fresenius Kabi and billed per 0.1 mg unit when the product is not therapeutically equivalent to J9041.
Workflow example: The hematology/oncology clinic documents the diagnosis and treatment plan during an office visit. The pharmacy verifies the bortezomib product and dose, prepares the vial or syringe under sterile conditions in the infusion suite or pharmacy clean room, and delivers it for administration. Nursing verifies patient identity, obtains consent, reviews pre-medication and baseline labs (complete blood count, liver function tests), and administers the injection or intravenous push/infusion according to protocol. Post-administration monitoring for neuropathy, cytopenias, and infusion reactions occurs in the same infusion center or hospital outpatient infusion unit. Billing uses J9048 with appropriate units reflecting the total milligrams administered divided by 0.1 mg units, and relevant modifiers to indicate circumstances such as billing for discarded drug (JW) or patient status modifiers.
Coding Specifications
| Modifier |
|---|